biotech / news / / The Manila Times
2026 patient audit data from Spherix Global Insights reveals biologic use nearing 60% of patients.
Biologic therapies are now used in nearly 60% of moderate-to-severe SLE patients.
KEY POINTS
- Subcutaneous Saphnelo is expected to drive significant patient switching from Benlysta due to convenience.
- Only 11% of SLE patients are in remission, with nearly half still experiencing moderate or high disease activity.
- One in five rheumatologists have referred a patient to a cell therapy trial for SLE in the past year.
- A substantial portion of SLE patients remain biologic-eligible but untreated, representing growth potential for new therapies.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →